Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Belumosudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 18/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 10/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 1.00 |
| ▸ | BLK | P51451 | 1/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 1.00 |
| ▸ | STK3 | Q13188 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 1/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 1.00 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 1.00 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Belumosudil SCHEMBL29361017 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL29364140 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL29575654 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL23777554 | 0.97 | ROCK2 (0.94) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL29362786 | 0.97 | ROCK2 (0.94) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL30634521 | 0.97 | ROCK2 (0.94) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL878258 | 0.96 | ROCK2 (0.91) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL31151877 | 0.94 | ROCK2 (0.88) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL877618 | 0.93 | ROCK2 (0.87) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL877914 | 0.91 | ROCK2 (0.84) | ROCK2ROCK1CLK2BLKCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097036-A1 | Liquid Formulation of Belumosudil | KADMON CORPORATION, LLC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | claimed |
| US-20260027116-A1 | Methods of Treating Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation | KADMON CORPORATION, LLC (US) | 2026-01-29 | — | — | US | claimed |
| US-20260007673-A1 | ROCK2 INHIBITORS FOR THE TREATMENT OF VIRAL INFECTIONS | GRAVITON BIOSCIENCE BV (NL) | 2026-01-08 | — | — | US | claimed |
| EP-3595649-B1 | 5-((2R,4AR,10BR)-9-ETHOXY-2-HYDROXY-8-METHOXY-1,2,3,4,4A,10B-HEXAHYDRO-PHENANTHRIDIN-6-YL)1-METHYL-1H-PYRIDIN-2-ONE FOR USE IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | TAKEDA PHARMACEUTICALS CO (JP) | 2025-10-01 | — | — | EP | claimed |
| US-20250255867-A1 | Belumosudil for Treating Chronic Lung Allograft Dysfunction | KADMON CORPORATION, LLC (US) | 2025-08-14 | — | — | US | claimed |
| EP-4554593-A1 | METHODS OF ADMINISTERING BELUMOSUDIL FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE IN PATIENT SUBPOPULATIONS | Kadmon Corporation, LLC (US) | 2025-05-21 | — | — | EP | claimed |
| EP-4554591-A1 | METHODS OF ADMINISTERING BELUMOSUDIL FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE | Kadmon Corporation, LLC (US) | 2025-05-21 | — | — | EP | claimed |
| US-20240408095-A1 | Method of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease | KADMON CORPORATION, LLC (US) | 2024-12-12 | — | — | US | claimed |
| US-20240366604-A1 | SELECTIVE INHIBITORS OF ROCK2 FOR THE TREATMENT OF MUSCULAR DYSTROPHY | GRAVITON BIOSCIENCE BV. (NL) | 2024-11-07 | — | — | US | claimed |
| US-8916576-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, INC. (US) | 2014-12-23 | — | — | US | claimed |
| US-20130131047-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2013-05-23 | — | — | US | claimed |
| US-8357693-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, INC. (US) | 2013-01-22 | — | — | US | claimed |
| US-20120202793-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2012-08-09 | — | — | US | claimed |
| EP-2406236-A1 | RHO KINASE INHIBITORS | Surface Logix, Inc. (US) | 2012-01-18 | — | — | EP | claimed |
| WO-2010104851-A1 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2010-09-16 | — | — | WO | claimed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | claimed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | claimed |
| EP-1865958-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | Surface Logix, Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006105081-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-10-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366604-A1 | SELECTIVE INHIBITORS OF ROCK2 FOR THE TREATMENT OF MUSCULAR DYSTROPHY | MYLK2, MYLK3, ROCK2 | ROCK2 3/4885ROCK1 10/4885CLK2 339/4885 |
| US-20260027116-A1 | Methods of Treating Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation | JAK1, IL2, IFNG | ROCK2 56/4885ROCK1 112/4885CLK2 179/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | ROCK2 1/4885ROCK1 4/4885CLK2 337/4885 |
| US-20130131047-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
| US-20260097036-A1 | Liquid Formulation of Belumosudil | ROCK2, ROCK1, MYLK | ROCK2 1/4885ROCK1 2/4885CLK2 89/4885 |
| US-20250255867-A1 | Belumosudil for Treating Chronic Lung Allograft Dysfunction | BAK1, BAD, CYSLTR1 | ROCK2 165/4885ROCK1 33/4885CLK2 1781/4885 |
| US-20240408095-A1 | Method of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease | MCL1, BAD, BAK1 | ROCK2 113/4885ROCK1 56/4885CLK2 2830/4885 |
| US-20100144707-A1 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
| US-20120202793-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CLK2 330/4885 |
| US-20260007673-A1 | ROCK2 INHIBITORS FOR THE TREATMENT OF VIRAL INFECTIONS | ROCK2, PIM2, ROCK1 | ROCK2 1/4885ROCK1 3/4885CLK2 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.